Gene clue to how virus causes cancer

March 19, 2012 By Sam Wong
Gene clue to how virus causes cancer

Virologists and immunologists at Imperial College London and University of Zurich have identified mutations in Epstein-Barr virus (EBV) that increase the capacity of the virus to cause cancer, in a study published this week in the Journal of Clinical Investigation. The research reveals that EBV carries a tumor suppressor gene – the first such gene known in a cancer-causing virus.

EBV is one of the most common viruses in humans, persistently infecting more than 90 per cent of the population. The can remain in the body for many years without any obvious symptoms, but it also causes glandular fever and is associated with several types of cancer, including lymphoma.

The new research has found that EBV normally carries a gene that suppresses cancer, at least in part by alerting the host immune system to the infected . that inactivate this gene allow the virus to escape detection by the immune system and cause cancer.

The researchers studied the effect of mutations in the EBNA3B gene in mice engineered to carry components of the human immune system. When these mice were infected with normal EBV, the reconstituted immune system was able to control the growth of the infected cells. When they were infected with EBV with EBNA3B deleted, they developed aggressive lymphomas – tumors formed from immune cells called B lymphocytes.

B cells infected with the normal EBV virus secreted a protein called CXCL10 that attracts T cells, another type of lymphocyte. T cells travel to sites of infection and inflammation and some can eliminate abnormal cells. If the virus lacked EBNA3B however, the B cells failed to produce CXCL10, which could explain why they were able to evade the immune system and develop into tumors.

The researchers also sequenced DNA from samples of human lymphomas linked to EBV, and identified mutations in EBNA3B in three different types of EBV-positive lymphoma.

“This is the first known example of a cancer-causing virus carrying a tumour suppressor gene,” said Professor Martin Allday, from the Department of Medicine at Imperial College London, who led the study with Professor Christian Münz at the University of Zurich. “We can speculate that this gene might help ensure the long-term survival of the host without serious disease, which allows the virus to persist in human populations.

"The findings have highlighted the importance of factors like CXCL10 that attract immune cells in the surveillance of tumors. Understanding how these factors are regulated and work in tumours may assist in the development of better strategies for manipulating the in cancer therapies.”

The research at Imperial was funded by the Wellcome Trust, with additional support from Leukemia & Lymphoma Research and the UK Children’s Cancer and Leukaemia Group. The research at the University of Zurich was mainly supported by Cancer Research Switzerland with additional contributions by the National Cancer Institute, the Sassella Foundation, the Association for International Research, the Vontobel Foundation, Novartis, and the Swiss National Science Foundation.

Explore further: NIH scientists outline steps toward Epstein-Barr virus vaccine

More information: RE White et al. 'EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.' Journal of Clinical Investigation, 12 March 2012. doi:10.1172/JCI58092

Related Stories

NIH scientists outline steps toward Epstein-Barr virus vaccine

November 2, 2011
Epstein-Barr virus (EBV) infects nine out of ten people worldwide at some point during their lifetimes. Infections in early childhood often cause no disease symptoms, but people infected during adolescence or young adulthood ...

Researchers find Epstein Barr-like virus infects and may cause cancer in dogs

March 12, 2012
More than 90 percent of humans have antibodies to the Epstein Barr virus. Best known for causing mononucleosis, or "the kissing disease," the virus has also been implicated in more serious conditions, including Hodgkin's, ...

A single protein helps the body keep watch over the Epstein-Barr virus

February 17, 2012
Some 90 percent of people are exposed to the Epstein Barr virus (EBV) at some point in their life. Even though it is quickly cleared from the body, the virus can linger silently for years in small numbers of infected B cells. ...

Recommended for you

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.